EnGeneIC

EnGeneIC develops targeted anti-cancer therapies using its proprietary EDV (EnGeneIC Dream Vector) nanocell platform, a first-in-class cyto-immunotherapy that targets tumors directly while leveraging the patient's own immune system. The company's EDV nanocells can be loaded with various therapeutic agents and are designed to deliver treatments specifically to cancer cells, minimizing systemic side effects. EnGeneIC is conducting clinical trials including a recurrent glioblastoma trial, targeting an aggressive and currently incurable form of brain cancer, with the first patient already dosed. Founded in 2000 and headquartered in Lane Cove, Australia, the company has raised approximately $25M in Series B funding from investors including GRT Capital Partners, CHAMP Ventures, and Riverland Capital. EnGeneIC differentiates itself through its unique nanocell delivery platform that combines targeted drug delivery with immune system activation for oncology applications.